| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| 10058-F4; 10058-F4 | CFN60158 | 403811-55-2 | C12H11NOS2 = 249.35 | 5mg | QQ客服：1457312923 |
| 苯林若斯特; Belinostat (PXD101) | CFN60159 | 414864-00-9 | C15H14N2O4S = 318.35 | 5mg | QQ客服：2159513211 |
| Hesperadin; Hesperadin | CFN60160 | 422513-13-1 | C29H32N4O3S = 516.65 | 5mg | QQ客服：1457312923 |
| Sotrastaurin; Sotrastaurin | CFN60161 | 425637-18-9 | C25H22N6O2 = 438.48 | 5mg | QQ客服：1457312923 |
| Necrostatin-1; Necrostatin-1 | CFN60162 | 4311-88-0 | C13H13N3OS = 259.33 | 5mg | QQ客服：2159513211 |
| 凡德他尼; Vandetanib | CFN60163 | 443913-73-3 | C22H24BrFN4O2 = 475.35 | 5mg | QQ客服：1413575084 |
| 帕唑帕尼; Pazopanib | CFN60164 | 444731-52-6 | C21H23N7O2S = 437.52 | 5mg | QQ客服：1413575084 |
| 瑞卡帕布磷酸盐; Rucaparib (AG-014699) phosphate | CFN60165 | 459868-92-9 | C19H18FN3O.H3PO4 = 421.36 | 5mg | QQ客服：1413575084 |
| 阿螺旋霉素盐酸盐; Alvespimycin (17-DMAG) HCl | CFN60166 | 467214-21-7 | C32H48N4O8.HCl = 653.21 | 5mg | QQ客服：2056216494 |
| ZSTK474; ZSTK474 | CFN60167 | 475110-96-4 | C19H21F2N7O2 = 417.41 | 5mg | QQ客服：1413575084 |
| 甲苯磺酸索拉非尼; Sorafenib Tosylate | CFN60168 | 475207-59-1 | C21H16ClF3N4O3.C7H8O3S = 637.03 | 5mg | QQ客服：1457312923 |
| NVP-AEW541; NVP-AEW541 | CFN60169 | 475489-16-8 | C27H29N5O = 439.55 | 5mg | QQ客服：1413575084 |
| PHA-665752; PHA-665752 | CFN60170 | 477575-56-7 | C32H34Cl2N4O4S = 641.61 | 5mg | QQ客服：2056216494 |
| 托法替尼; Tofacitinib (CP-690550) | CFN60171 | 477600-75-2 | C16H20N6O = 312.37 | 5mg | QQ客服：1457312923 |
| 地塞米松; Dexamethasone | CFN60172 | 50-02-2 | C22H29FO5 = 392.46 | 5mg | QQ客服：2056216494 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)